FDAnews
www.fdanews.com/articles/101561-fovea-genzyme-ink-ophthalmology-agreement

Fovea, Genzyme Ink Ophthalmology Agreement

November 28, 2007

French drugmaker Fovea Pharmaceuticals has signed an agreement with Genzyme to identify targets involved in photoreceptor degeneration in retinal dystrophies.

The companies will collaborate to develop gene-related therapies using targets selected by Fovea and Genzyme’s gene delivery technologies, Fovea said.

Fovea has internal research programs on dry age-related macular degeneration, glaucoma and retinal dystrophies.